Jamie Christensen - 23 May 2022 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role
EVP, Chief Scientific Officer
Signature
/s/ Elizabeth Gelfand, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
23 May 2022
Net transactions value
-$39,649
Form type
4
Filing time
14 Jun 2022, 16:35:20 UTC
Previous filing
18 Jan 2022
Next filing
09 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRTX Common Stock Sale $39,649 -624 -0.71% $63.54 86,804 23 May 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on May 21, 2020.

Remarks:

This Form 4 is being filed late due to inadvertent administrative error.